Abbott Laboratories (ABT)
Technical, fundamental, and sentiment analysis with recent related videos.
ABT rates Neutral overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.95); revenue is growing about 0.7% per year; net income is growing about 21.8% per year. The technical picture is bullish: price is 4.0% above the 200-day moving average; 0.4% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 6 news articles and 2 qualified videos from recent coverage.
Revenue 3-year avg +0.7%. Net income 3-year avg +21.8%.
Price vs 20DMA +4.0%. RSI 58.06. Bollinger state: Inside Bands.
Composite score 72/100 from the AI judge, based on 6 news items, 0 television segments, and 2 videos.
Latest Market Read
Abbott’s ratings are split. Fundamentals are Neutral: revenue averaged 0.7 percent per year over three years while net income averaged 21.8 percent per year, but recent net-income weakness keeps the fundamental label in the middle. Technical is Bullish: the Relative Strength Index (RSI), a momentum reading, sits at 58.1, price is 4.0 percent above the 20-day moving average (the average closing price over the last 20 trading days), and the stock is inside the Bollinger Bands (a volatility price channel). Sentiment is Bullish with a 72 composite. The mix of Neutral fundamentals and positive technical plus bullish sentiment produces an Overall Neutral rating.
Recent news: Global Database of Events, Language, and Tone (GDELT) coverage and press reports highlight $7.4B in free cash flow, Abbott’s new Oncodetect MRD cancer test launch, a Wells Fargo price-target raise to $119, and an institutional stake increase, while Q3 results were mixed. Internet Archive TV segments and recent videos focused on shares falling after the planned $8.5B nutrition-unit spin-off and coverage also noted Abbott raising 2026 profit guidance.